Compare BioNano Genomics Inc (BNGO) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.22. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | VEA | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | — |
52-Week High | $4.92 | $72.89 |
52-Week Low | $1.06 | $58.19 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
VEA trades at $73.31, up 1.12% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with both new acquisitions and position reductions. Recent news highlights VEA's competitive advantages in expense ratios and international diversification compared to peers like SPGM and NZAC.
Outlook remains positive given strong technical momentum and cost advantages, though overbought RSI signals near-term caution. Key risks include international market volatility and currency fluctuations. The ETF's low-cost structure and developed market exposure provide long-term diversification benefits for US investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
